Lung Cancer
Conference Coverage
SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLC
ATLANTA – Preclinical data suggest a role for SRA737 plus anti–PD-L1 therapy and low-dose gemcitabine in SCLC.
Conference Coverage
PACIFIC: Patient-reported outcomes unaffected by PD-L1 expression
GENEVA – Level of programmed death-ligand 1 expression does not impact patient-reported outcomes among those...
Conference Coverage
Novel CAR T, anti-PD-1 combo shows promise in MPD
ATLANTA – Intrapleurally administered, mesothelin-targeted CAR T-cell therapy combined with PD-1 inhibition showed antitumor activity without...
Conference Coverage
Pooled KEYNOTE data support pembro for elderly patients with NSCLC
GENEVA – Investigators analyzed data from 264 patients 75 years or older involved in the KEYNOTE-010, KEYNOTE-024,...
Conference Coverage
Tumor-treating fields boost chemo for mesothelioma
GENEVA - Patients with malignant pleural mesothelioma who were treated with TTFields in combination with pemetrexed and...
News
FDA approves pembrolizumab for first-line stage III NSCLC
Approval was based on improved overall survival for patients taking pembrolizumab, compared with those taking the investigators’ choice of...
News
Five-fraction SRBT schedule well tolerated with high tumor-control rate in central lung cancers
The five-fraction schedule delivered in a phase 1/2 study of 120 patients with centrally located non–small cell lung cancer was associated with a...
News
Plasma genotyping yields actionable mutation in advanced NSCLC
Noninvasive ultra-deep sequencing of cell-free plasma DNA identified driver mutations with results comparable to those of genotyping of biopsied...
Conference Coverage
Higher dose of checkpoint inhibitor every 4 weeks feasible in NSCLC
SAN FRANCISCO – The 6-month PFS rates were similar for patients treated every 2 or 4 weeks, but the trial could not show noninferiority of...
Conference Coverage
Rare, aggressive NSCLC type yields to pembrolizumab
SAN FRANCISCO – Pulmonary sarcomatoid carcinoma tumors have high mutational burden and PD-L1 expression, making them ideal targets for immune...
